A Multiannual TIF Project aimed at tackling Haemoglobinopathies on the move.
Thalassaemia, a previously fatal childhood genetic disease, can today be effectively prevented and adequately treated, as a result of the medical and scientific advances that took place in the last three decades. However, thalassaemia’s prioritisation on national health agendas and the development of national plans for its effective control in the EU has been hampered by the many challenges involved, mainly related to its rarity and migration.
THALassaemia In Action (THALIA) focuses on Europe, targeting patients with thalassaemia and other haemoglobinopathies, healthcare professionals and policymakers.
THALIA is funded by the European Union under the Specific Grant Agreement (SGA) No. 101083240. Views and opinions expressed are however those of the author(s) only and do not reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.